Background {#S0001}
==========

Chronic lymphocytic leukemia (CLL) is a clonal disorder that results in the accumulation of morphologically mature-looking and immunologically incompetent lymphoid cells in the bone marrow, peripheral blood, and lymphatic tissues.[@CIT0001],[@CIT0002] Until recently, it was thought that CLL developed mainly from impaired apoptosis and evasion of cell death; however, it has been acknowledged that CLL-affected tissue comprising the bone marrow contains proliferation centers that support the top-up theory of the CLL cell population.[@CIT0003]--[@CIT0005] CLL is a heterogeneous disease as some patients may progress rapidly, even though they may fail to respond to therapy, and others may remain stable for years without any intervention, and this mirrors the genetic configuration and the epigenetic modification of different genes that lead to disease development, stability, progression, and response to different chemotherapeutic agents.[@CIT0006],[@CIT0007]Table 1Correlation Of *TP53* Gene Methylation Status To Hematological Data And Staging CategoriesParametersDifferent CategoriesMethylatedUn-MethylatedTotal*P* valueNo.%No.%Hemoglobin level (g/dl)\>10.0916.673870.3747 (87.04%)0.167Hb \< 10.035.5547.417 (12.96%)Platelets (\*10^9^/L)\>100712.963768.5244 (81.48)0.047\< 10059.2659.2610 (18.52%)WBC count (\*10^9^/L)\< 501018.534074.0750 (92.59%)0.144\>5023.7023.704 (7.41%)Lymphocytes count (\*10^9^/L)5--2059.32138.926 (48.15%)0.425\> 2071.9213.728 (51.85%)StageA59.32444.429 (53.70%)0.076B23.7132415 (27.78%)C59.359.310 (18.52%)

Epigenetic modification may result from different strategies including DNA methylation/hypomethylation, histone alterations, and chromatin conversion. The epigenetic alteration has significant roles in controlling different genes\' activities, genomic imprint, reproduction, embryonic development, inactivation of the X chromosome, tissue remodeling, as well as in disease pathogenesis, progression, and chemo-refractoriness.[@CIT0008]--[@CIT0012] DNA methylation arises as a consequence of the addition of a methyl group to cytosine in the CpG dinucleotides that are characteristically seen as collections in small stretches of DNA termed "CpG islands" in the promoter regions of different housekeeping, the tumor suppressor, and some tissue-specific genes.[@CIT0013],[@CIT0014] Hypermethylation in the promoter regions through the action of DNA methyltransferases enzyme results in gene suppression and inactivation, while hypomethylation results in gene activation.[@CIT0008],[@CIT0015]

Protein 53 (p53), an end product for the *TP53* gene, plays a dynamic role in sustaining genetic stability and regulating the cellular response to DNA damage and other replicative stresses. Activation of p53 can ultimately lead to either DNA repair or programmed cell death, thus preventing cancer formation, i.e., it functions as a tumor suppressor and *TP53* is classified as a tumor suppressor gene.[@CIT0016] Inactivation of the *TP53*gene through different mutations like in Li-Fraumeni syndrome or hypo-activation through epigenetic alteration by methylation impairs apoptosis and may lead to many types of cancers, including CLL.[@CIT0017]

The current study was initiated to estimate the effect of methylation of different genes functions and to correlate the *TP53* non-functioning (through methylation) with the pathogenesis and progression of CLL.

Methods {#S0002}
=======

The current study represents a case-control study. A total of 54 newly diagnosed patients with CLL attending Nanakali hospital for blood diseases in Erbil, Iraq from January 1, 2017 to July 30, 2018 were enrolled. These patients were diagnosed as described by WHO criteria, which include absolute lymphocytosis (absolute lymphocytosis \>5\*10^9^/L) with typical immunological expression by flowcytometry.[@CIT0005] Also, 30 age- and sex-matched individuals with a negative history of previous "hematological and non-hematological malignancies" were recruited for the purpose of the current study and used as controls. At first, verbal informed consent was obtained from all enrolled patients and the study was approved by the appropriate ethical committee at the University of Duhok College of Medicine and Duhok Directorate of Health, Duhok, Iraq and followed the Declaration of Helsinki ethical values for medical research concerning human beings.

Supportive information was collected from all enrolled individuals and then blood (also bone marrow sample was taken from patients) were collected in K2-EDTA tubes from each enrollee and all had their DNA extracted by a modified salting-out extraction method adopted by Iranpur-Mubarakeh and his colleague that yield high quantity with high purity DNA.[@CIT0018],[@CIT0019]

The methylation-specific polymerase chain reaction (MS-PCR) technique was used in the current study, which requires an initial conversion of DNA structure and then amplification using specific primer sets for methylated and unmethylated DNA targets.[@CIT0020]

At first, DNA bisulfite conversion is done with the aid of the EpiTect fast bisulfite conversion kit from Qiagen (Germany) and all steps were done according to the manufacturer\'s instructions. Then the converted DNA samples were amplified using M-P53-F 5ʹ-TTCGGTAGGCGGATTATTTG-3ʹ and M-P53-R 5ʹ-AAATATCCCCGAAACCCAAC-3ʹ primers for the methylated *TP53*gene and U-P53-F 5ʹ-TTGGTAGGTGGATTATTTGTTT-3ʹ and U-P53-R 5ʹ-CCAATCCAAAAAAACATATCAC-3ʹ primers for the un-methylated *TP53*gene.[@CIT0021] Initially a master mix was prepared using 2X Hot Start Master Mix from GeNet Bio (South Korea) and then amplification was performed using a PCR thermal cycler (2720) from Applied Biosystems, Hitachi (Japan). PCR conditions were as follows: for methylated *TP53*gene (94°C for 5 min, 35 cycles at 94°C for 30 s, 60°C for 40 s, 72°C for 60 s, 72°C for 7 min) and for unmethylated gene (94°C for 5 min, 35 cycles at 94°C for 30 s, 53°C for 40 s, 72°C for 60 s, 72°C for 7 min). Finally, the amplified products were subjected to 2% agarose gel electrophoresis. As shown in [Figure 1](#F0001){ref-type="fig"}, the methylated DNA sample produced a 193-bp DNA product with the M-P53 primers set, while the unmethylated DNA samples produced no band. On the other hand, the unmethylated DNA samples produced a 247-bp DNA product with the U-P53 primers set, while the methylated DNA samples produced no band. Appropriate methylated and unmethylated DNA controls were obtained from Qiagen \[Epitec®Control DNA (Human), unmethylated and bisulfite converted (100)\] and ran in parallel to patients' samples in all runs.Figure 1Gel electrophoresis of amplified products with U-P53 primers for determination of P53 methylation status. L: represents the 100-bp ladder; CU: unmethylated commercial P53 control DNA (247 bp); C-M: methylated commercial P53 control DNA; 1, 2, & 4 reveals unmethylated P53 DNA patient samples; and 3: represents methylated P53 DNA patient samples.

After data collection, data were analyzed using SPSS 24. Frequency and frequency percentages were used to describe the study sample. Student's *t*-test was used for continuous variables, and chi-square or Fisher exact test were used for categorical variables. *P*-value was considered to be significant if less than 0.05.

Results {#S0003}
=======

A total of 54 patients with CLL were enrolled in the current study. Their ages ranged from 44 to 80 years with a median age of 62.2 ± 8.2 years. Of these, 37 (68.5%) were male and 17 (31.5%) were female, with a male to female ratio of 2.18.

After amplification with specific primers designed for determination of *TP53*gene methylation status, samples from 42 patients (77.8%) and all 30 controls (100%) show a 247-bp pattern with U-P53 (F&R) primers that is consistent with unmethylation status ([Figure 1](#F0001){ref-type="fig"}). On the other hand, samples from 12 patients (22.2%) revealed no band with U-P53 (F&R) primers, but show a 193-bp band with M-P53 (F&R) primers, which is consistent with methylation status ([Figure 2](#F0002){ref-type="fig"}). The methylated status was seen among 17.6% of female patients (3 females) and only among 23.1% of male patients (9 males) with a *p*-value of 0.539.Figure 2Gel electrophoresis of amplified products with M-P53 for determination of P53 methylation status. L: represents the 100-bp ladder; CM: methylated commercial P53 control DNA (193 bp); CU: unmethylated commercial P53 control DNA; 1 & 2 reveal methylated P53 DNA patient samples; and 3: represents unmethylated P53 DNA patient samples.

Methylated P53 had been associated significantly with CLL groups in comparison to controls with a *p*-value of \<0.001. Using a *t*-test as shown in [Table 1](#T0001){ref-type="table"}, the methylated status shows a significant correlation with low platelet count (*p*-value 0.047) as well as advanced stage (*p*-value 0.076); despite this, it does not show a significant correlation with hemoglobin level (*p*-value 0.167), total white blood cell count (*p*-value 0.144), and absolute lymphocytes count (*p*-value 0.425).

Discussion {#S0004}
==========

The exact mechanism underlying CLL is still unclear; nevertheless, various molecular changes (genetic and epigenetic) have been implicated in CLL tumorigenesis and disease progression.[@CIT0001],[@CIT0022]

From these, *TP53* gene modification disturbs the process of apoptosis and results in prolonged survival of the malignant B cells in tissue and peripheral blood.[@CIT0023] Also, *TP53* inactivation had been criticized for fludarabine resistance in 30--40% of patients with CLL, the backbone drug for this leukemia. Only a quarter of cases had contributed to *TP53* gene deletion and the remaining three-fourths had contributed to gene inactivation through methylation of the promoter region of the gene.[@CIT0024],[@CIT0025] As the methylation results in gene inactivation and in accordance with the previous review written by Wang and Wang, the current study revealed a significant association of *TP53* gene promoter methylation with the CLL development.[@CIT0026] Not only the pathogenesis but also the advanced stage (low platelets) had been associated significantly with *TP53* gene suppression as through promoter methylation and this poor prognosis was in accordance with the previous study conducted by Zenz and his coworkers.[@CIT0023],[@CIT0025] On the other hand, methylation of the *TP53* gene promoter was not significantly associated with low hemoglobin level or high total white cells counts, and this may explain the heterogeneous nature of CLL and its correlation with other gene malfunctions. The various effect of *TP53* methylation on platelet count, hemoglobin level, and total white cell count may represent the different effects of *TP53* dysfunction on the micro-environment and interaction of different genes with the hemopoietic proliferation and maturation.[@CIT0027],[@CIT0028]

Epigenetic modification of promoters of different genes contributes to gene activation or suppression as a result of hypo- or hypermethylation, respectively, and targeting this mechanism, e.g., with 5-aza-2ʹ-deoxycytidine (5-aza-dC) that upregulates expression of *TP53* mRNA and protein, may be valuable in fighting CLL in the future as such drugs have been used extensively in myelodysplastic syndrome with excess blasts that show a characteristically high ratio of hypermethylation and different gene inactivation.[@CIT0029]

Follow-up of the patients involved in the current study has been initiated to determine the effect of the methylation on the progression of the disease and the response to various chemotherapeutic agents.

Conclusion {#S0005}
==========

The current study revealed that *TP53* methylation contributes significantly to CLL development and progression. Further workups are recommended to study their relation with other genetic changes as malignancies are multifactorial and heterogeneous that arise from the interaction of different genetic changes.
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=============

CLL, chronic lymphocytic leukemia; *TP53*, tumor protein 53; WBC, white blood cells; K2-EDTA, dipotassium-ethylenediaminetetraacetic acid; PCR, polymerase chain reaction; CPG, cytosine--guanine dinucleotide.
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